Skip to main content
ALCAlcon Inc.Hold5.2·$70.50-2.19%
HoldModerate Confidence
Investment thesis

Alcon's confirmed price downtrend and a put-to-call ratio of 3.70 reflect significant near-term bearish sentiment — though rising analyst estimates, 19% upside to the consensus target, and strong cash conversion suggest the setup could improve materially if the earnings momentum visible in three of the past four quarters persists.

Thesis pillars

  • Death Cross Confirmed DowntrendStable
  • Elevated Put Call Ratio Bearish PositioningDeteriorating
  • Rising Estimates Offset Weak GrowthDeteriorating
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Alcon Inc. (ALC) Stock Analysis

HoldShortModerate Confidence

Healthcare · Medical Instruments & Supplies

Hold if already holding. Not a fresh buy at $70.50, but acceptable to hold if already in. Reasons: Thin upside margin: 8.8%; Earnings estimates trending DOWN.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and... Read more

$70.50+8.8% A.UpsideScore 5.2/10#18 of 30 Medical Instruments & Supplies
QualityF-score9 / 9FCF yield3.73%
IncomeYield0.50%(5y avg 0.29%)Payout27.03%sustainable
Stop $68.37Target $76.72(analyst − 10%)A.R:R 1.8:1
Analyst target$85.24+20.9%15 analysts
$76.72our TP
$70.50price
$85.24mean
$62
$103

Hold if already holding. Not a fresh buy at $70.50, but acceptable to hold if already in. Reasons: Thin upside margin: 8.8%; Earnings estimates trending DOWN. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.2/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 66d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-09-05
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Nov 10, 202666d to earnings· next earnings call

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Risks
Thin upside margin: 8.8%
Earnings estimates trending DOWN
Negative momentum

Key Metrics

P/E (TTM)55.1
P/E (Fwd)17.7
Mkt Cap$34.1B
EV/EBITDA15.8
Profit Mgn5.9%
ROE2.9%
Rev Growth8.7%
Beta0.70
Dividend0.50%
Rating analysts22

Quality Signals

Piotroski F9/9MoatNarrow

Options Flow

P/C2.29bearish
IV35%normal
Max Pain$68-4.3% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Obv
1.0
Volume
2.4
Rsi
3.5
Ma Position
3.5
Volume distribution (falling OBV)Below 200-MA, MA slope flat
GatesMomentum 2.1<4.5Death cross (50MA < 200MA)A.R:R 1.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 66d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
38 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $70.48Resistance $76.20

Price Targets

$68
$77
A.Upside+8.8%
A.R:R1.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! momentum at 2.1 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-11-10 (66d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ALC stock a buy right now?

Hold if already holding. Not a fresh buy at $70.50, but acceptable to hold if already in. Reasons: Thin upside margin: 8.8%; Earnings estimates trending DOWN. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $76.72 (+8.8%), stop $68.37 (−3.1%), A.R:R 1.8:1. Score 5.2/10, moderate confidence.

What is the ALC stock price target?

Take-profit target: $76.72 (+8.8% upside). Target $76.72 (+8.8%), stop $68.37 (−3.1%), A.R:R 1.8:1. Stop-loss: $68.37.

What are the risks of investing in ALC?

Thin upside margin: 8.8%; Earnings estimates trending DOWN; Negative momentum.

Is ALC overvalued or undervalued?

Alcon Inc. trades at a P/E of 55.1 (forward 17.7). TrendMatrix value score: 5.5/10. Verdict: Hold.

What do analysts say about ALC?

22 analysts cover ALC with a consensus score of 3.8/5. Average price target: $85.

What does Alcon Inc. do?Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates...

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Related stocks: NVST (Envista Holdings Corporation) · TFX (Teleflex Incorporated) · MMED (MiniMed Group, Inc.) · WST (West Pharmaceutical Services, I) · MDLN (Medline Inc.)
Home Stocks ALC

Latest news

Latest News

Benzinga4d agoCONCERN
GuruFocus129d ago
Newser129d ago
TechStock²25d ago
The Globe and Mail25d agoAnalyst
Yahoo Finance25d ago
Quiver Quantitative123d ago
Marketscreener.com128d ago
MSN128d agoMerger Acquisition
Yahoo Finance125d ago
DirectorsTalk Interviews131d ago
TipRanks26d agoEarnings
Scanx.trade26d agoEarnings
Quiver Quantitative26d agoEarnings
Investing.com South Africa26d agoEarnings
Quiver Quantitative26d ago
Marketscreener.com26d agoEarnings
Business Wire26d agoProduct
AD HOC NEWS26d agoEarnings
DirectorsTalk Interviews26d ago
Loading more...